Acorda Hits Back At Hedge Fund Manager In PTAB Challenge
Acorda Therapeutics Inc. pushed back Tuesday against a challenge to its multiple sclerosis drug Ampyra by an organization with close ties to a hedge fund manager, telling the Patent Trial and...To view the full article, register now.
Already a subscriber? Click here to view full article